# Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or Melanoma

> **NCT00512798** · PHASE1,PHASE2 · TERMINATED · sponsor: **Vanderbilt-Ingram Cancer Center** · enrollment: 47 (actual)

## Conditions studied

- Brain and Central Nervous System Tumors
- Melanoma
- Solid Tumor

## Interventions

- **DRUG:** PS-341 (VELCADE)
- **DRUG:** temozolomide
- **OTHER:** immunoenzyme technique
- **DRUG:** PS-341 (VELCADE)
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT00512798
- **Lead sponsor:** Vanderbilt-Ingram Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-06
- **Primary completion:** 2006-07
- **Final completion:** 2008-03
- **Target enrollment:** 47 (ACTUAL)
- **Why stopped:** This study was terminated due to lack of efficacy
- **Last updated:** 2012-10-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00512798

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00512798, "Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or Melanoma". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00512798. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*